EUCTR2009-017671-22-BE进行中（未招募）不适用
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Commercially Available Therapies
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Have recurrent, locally advanced or metastatic breast cancer that has progressed on or after the last anti-cancer therapy
- •Had prior treatment with, ineligibility for, or commercial unavailability of each of the following therapies:
- •o Anthracyclines, taxanes, and capecitabine
- •o Ixabepilone, in countries where this agent is marketed
- •o Trastuzumab, for Her-2 positive disease
- •o Hormonal therapy, in hormone receptor-positive disease
- •o All other commercially available therapies, e.g. gemcitabine or vinorelbine, used for the treatment of advanced breast cancer (See NCCN guidelines)
- •Have an ECOG performance status = 2
- •Have a serum creatinine = 2.0 mg/dL or creatinine clearance = 40 mL/min according to Cockcroft and Gault formula
- •Have an absolute neutrophil count = 1.5 x 109/L, hemoglobin = 10 g/dL (can be corrected by growth factor or transfusion), and platelet count = 100 x 109/L
- •Have a total bilirubin = 1.5 x upper limit of normal (ULN). Alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase = 3 x ULN (= 5 x ULN in case of liver metastases). In case alkaline phosphatase is > 3 x ULN (in absence of liver metastases) or > 5 x ULN (in presence of liver metastases) AND patient also is known to have bone metastases, the liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase
- •Are willing and able to comply with all aspects of the treatment protocol
- •Provide written informed consent.
- •Are females, age = 18 years
- •Female subjects of childbearing potential must agree to be abstinent or to use a highly effective method of contraception (eg, condom + spermicide, condom + diaphragm with spermicide, intra-uterine device, or have a vasectomized partner) having started for at least one menstrual cycle prior to starting eribulin and throughout the entire treatment period and for 30 days (longer if appropriate) after the last dose of eribulin. Those women using hormonal contraceptives must also be using an additional approved method of contraception (as described previously). Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Are eligible for any other eribulin study that is open in the same region
- •Have existing anti-cancer therapy-related toxicities of grade = 2, except that alopecia and grade 2 neuropathy are acceptable
- •Have a history of congestive heart failure with New York Heart Association Classification > II, unstable angina, myocardial infarction within the past 6 months, serious cardiac arrhythmia
- •Have an electrocardiogram with QTc interval = 500 msec based upon Bazett’s formula (QTcB)
- •The Investigator believes the subject to be medically unfit to receive eribulin or unsuitable for any other reason
- •Are females who are pregnant (positive ß-hCG test) or breastfeeding
- •Are hypersensitive to eribulin or any of the excipients
- •Have brain or subdural metastases, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this treatment protocol. Any signs (eg, radiologic) and/or symptoms of brain metastases must be stable for at least 4 weeks before starting the treatment protocol
- •Have a history of or concomitant medical condition that, in the opinion of the Investigator, would compromise the subject’s ability to safely complete the treatment protocol
- •Are known to be human immunodeficiency virus positive because the neutropenia caused by the eribulin treatment may make such subjects particularly susceptible to infection.
- •Have meningeal carcinomatosis
- •Have pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen
- •Have received any of the following treatments within the specified period before the start of treatment:
- •o Any investigational drug within 4 weeks
- •o Chemotherapy, radiation, or biological or targeted therapy
- •within 2 weeks
- •o Hormonal therapy within 1 week.
研究者
相似试验
进行中（未招募）
1 期
Access Program for Asfotase AlfaHypophosphatasiaEUCTR2015-000809-39-FRAlexion Pharma International Sàrl100
进行中（未招募）
不适用
An expanded access program of ranibizumab in patients with visual impairment due to diabetic macular edema for whom no suitable therapeutic alternatives exist.EUCTR2011-002731-26-ITOVARTIS FARMA700
已完成
Unknown
Trastuzumab deruxtecan for subjects with HER2 mutated metastatic NSCLCJPRN-jRCT2071220096eno Shizuko30
Approved For Marketing
不适用
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyUrothelial CarcinomaNCT02589717Genentech, Inc.
进行中（未招募）
1 期
Clinical Study with the bispecific antibody Blinatumomab in pediatric and adolescent subjects with B-precursor Acute Lymphoblastic Leukemia (ALL) who did not respond to previous therapy or who relapsed after initial successful previous therapyEUCTR2014-001700-21-DEAmgen Inc.100